Sanofi announced positive results from the pivotal Phase 3 LIBERTY-AFRS-AIMS trial showing Dupixent significantly improved outcomes for adults and children aged 6 years and older with allergic fungal ...

A recently launched campaign starring patients and scientists shows Sanofi in hot pursuit of scientific innovation. | A ...

Sanofi has cited security concerns about planned highrises near its plant, while the developer says the provincial order ...

Sanofi is rolling out a new global campaign that features the stories of six real patients, to underscore its core purpose.

Sanofi’s stock narrative is shifting as analysts revise their consensus price target slightly downward, from $106.90 to $106.85. This minor adjustment reflects a careful reassessment of Sanofi’s ...

In November 2025, SOE Medical Procurement of Ukraine renegotiated the managed entry agreements (MEAs) with the international ...

Sanofi Consumer Healthcare India Limited said on Thursday that its third-quarter profit jumped 40% to ₹62.9 crore and revenue ...

The order is limited to Tenblock’s property and requests any new buildings be limited to 33 metres high, or about 10 storeys ...

The pharmaceutical company Sanofi reduced the supply of influenza vaccines to Ukraine by 60% in the current epidemic season - ...

Sanofi successfully prices USD 3billion of bond issue Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its ...

Sanofi's “Badge of Honor,” made with FCB Health New York, won gold for Data-Driven Campaign of the Year among suppliers, ...

ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal ...